{"id":"fk463","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1237070","moleculeType":"Small molecule","molecularWeight":"1292.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FK463 is an echinocandin antifungal that inhibits the enzyme 1,3-β-D-glucan synthase, which is essential for fungal cell wall integrity. By blocking glucan synthesis, the drug causes weakening and rupture of the fungal cell wall, resulting in fungal cell lysis and death. This mechanism provides broad-spectrum activity against many clinically important fungal pathogens.","oneSentence":"FK463 is a fungal cell wall synthesis inhibitor that disrupts β-glucan formation, leading to fungal cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:41.646Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive candidiasis"},{"name":"Invasive aspergillosis"}]},"trialDetails":[{"nctId":"NCT05178862","phase":"PHASE3","title":"A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole","status":"TERMINATED","sponsor":"Scynexis, Inc.","startDate":"2022-08-03","conditions":"Candidiasis, Invasive, Candidemia","enrollment":68},{"nctId":"NCT02805049","phase":"PHASE4","title":"Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis (EPI Study)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2017-01-28","conditions":"Septic Shock, Peritonitis","enrollment":24},{"nctId":"NCT02164890","phase":"PHASE4","title":"Pharmacokinetics of Micafungin in Patients of Intensive Care Units","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2014-06","conditions":"Invasive Candidiasis","enrollment":60},{"nctId":"NCT02145832","phase":"PHASE2, PHASE3","title":"Fluconazole Versus Micafungin in Neonates With Candidiasis","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2014-10","conditions":"Candidiasis","enrollment":100},{"nctId":"NCT07072923","phase":"PHASE4","title":"Antibiotic Impregnated Beads in Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","startDate":"2025-09-01","conditions":"Osteomyelitis of the Foot, Antibiotic Impregnated Beads, Osteomyelitis of Lower Extremities","enrollment":100},{"nctId":"NCT06907992","phase":"","title":"A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia","status":"NOT_YET_RECRUITING","sponsor":"Augusta University","startDate":"2025-05-01","conditions":"Candidemia","enrollment":150},{"nctId":"NCT01982071","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia","status":"TERMINATED","sponsor":"Astellas Pharma China, Inc.","startDate":"2013-09-26","conditions":"Candidemia, Candidiasis","enrollment":59},{"nctId":"NCT02646774","phase":"PHASE4","title":"Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis","status":"TERMINATED","sponsor":"Astellas Pharma China, Inc.","startDate":"2014-03-01","conditions":"Invasive Aspergillosis","enrollment":43},{"nctId":"NCT01122368","phase":"PHASE2","title":"A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-07-13","conditions":"Mycoses","enrollment":252},{"nctId":"NCT03421002","phase":"PHASE2","title":"Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-05-30","conditions":"Candidiasis, Systemic, Candida Meningitis","enrollment":35},{"nctId":"NCT01058174","phase":"PHASE3","title":"Liver Transplant European Study Into the Prevention of Fungal Infection","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-12-15","conditions":"Liver Transplantation, Mycoses","enrollment":350},{"nctId":"NCT00608335","phase":"PHASE1","title":"Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-10-14","conditions":"Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis","enrollment":84},{"nctId":"NCT02646800","phase":"PHASE4","title":"Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp","status":"TERMINATED","sponsor":"Astellas Pharma China, Inc.","startDate":"2014-03-21","conditions":"Aspergillosis, Candidiasis","enrollment":105},{"nctId":"NCT01686607","phase":"","title":"Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-10-01","conditions":"Systemic Fungal Infections","enrollment":40110},{"nctId":"NCT02127788","phase":"","title":"Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology","status":"COMPLETED","sponsor":"Astellas Pharma S.A.S.","startDate":"2014-07-03","conditions":"Antifungal Prophylaxis, Haemopathy","enrollment":150},{"nctId":"NCT03174457","phase":"","title":"Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2017-06-21","conditions":"Invasive Fungal Infections","enrollment":120},{"nctId":"NCT05784844","phase":"PHASE4","title":"Antimicrobial Revision in Persistent Febrile Neutropenia","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2024-08","conditions":"Febrile Neutropenia","enrollment":""},{"nctId":"NCT02244606","phase":"PHASE2","title":"Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis","status":"COMPLETED","sponsor":"Scynexis, Inc.","startDate":"2014-09","conditions":"Mycoses, Candidiasis, Invasive, Candidemia","enrollment":27},{"nctId":"NCT00304772","phase":"PHASE4","title":"Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients","status":"WITHDRAWN","sponsor":"Kyoto University","startDate":"2006-08","conditions":"Candidiasis, Sepsis","enrollment":""},{"nctId":"NCT06413056","phase":"PHASE4","title":"Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-10-20","conditions":"Neonatal Infection, Invasive Fungal Infections","enrollment":56},{"nctId":"NCT00839540","phase":"PHASE4","title":"Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins","status":"COMPLETED","sponsor":"Gary E. Stein, Pharm.D.","startDate":"2008-12","conditions":"Candidemia","enrollment":21},{"nctId":"NCT01814488","phase":"PHASE2","title":"A Phase II Study on Allogeneic Stem Cell Transplantation in Patients With Active Acute Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Trapianto di Midollo Osseo","startDate":"2013-07","conditions":"Acute Leukemia","enrollment":101},{"nctId":"NCT04728971","phase":"PHASE4","title":"To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2022-10-01","conditions":"Liver Transplantation","enrollment":200},{"nctId":"NCT05496725","phase":"PHASE4","title":"Evaluate Bioequivalence of Micafungin (50mg/Vial)","status":"COMPLETED","sponsor":"Yung Shin Pharm. Ind. Co., Ltd.","startDate":"2022-01-06","conditions":"Invasive Candidiasis","enrollment":14},{"nctId":"NCT01869829","phase":"","title":"PEACE: Pediatric Antifungal Comparative Effectiveness","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-01","conditions":"Pediatric Invasive Candidiasis","enrollment":750},{"nctId":"NCT02440178","phase":"PHASE2","title":"Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2015-09-19","conditions":"Acute Leukemia","enrollment":66},{"nctId":"NCT03906916","phase":"PHASE4","title":"Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin","status":"TERMINATED","sponsor":"Fadoi Foundation, Italy","startDate":"2018-07-18","conditions":"Invasive Candidiasis","enrollment":14},{"nctId":"NCT01950507","phase":"PHASE1","title":"Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease","status":"TERMINATED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2014-02-20","conditions":"Stem Cell Transplantation, Graft vs Host Disease","enrollment":15},{"nctId":"NCT04738955","phase":"PHASE4","title":"Efficacy and Safety of Micafungin for Injection in Prevention and Treatment of Fungal Infection in Hematological Tumors","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2021-02-01","conditions":"Hematological Tumors Patients With High Risk Factors of Invasive Fungal Disease","enrollment":230},{"nctId":"NCT02172768","phase":"PHASE2","title":"Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2014-10","conditions":"Acute Graft Versus Host Disease Grade II-IV, Allogeneic Stem Cell Transplant, Acute Myeloid Leucaemia","enrollment":30},{"nctId":"NCT01783379","phase":"","title":"Pharmacokinetics of Micafungin in Patients Intensive Care Unit","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2013-01","conditions":"Invasive Fungal Infection","enrollment":20},{"nctId":"NCT01090141","phase":"PHASE4","title":"Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2009-11","conditions":"Obesity, Nutrition Disorders, Overweight","enrollment":36},{"nctId":"NCT03102658","phase":"PHASE4","title":"Micafungin Pharmacokinetics in Obese Patients","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2017-01","conditions":"Morbid Obesity","enrollment":24},{"nctId":"NCT03752372","phase":"","title":"Microbiome Alterations in IL10RA-deficient Patients After HSCT","status":"TERMINATED","sponsor":"Children's Hospital of Fudan University","startDate":"2017-10-01","conditions":"Inflammatory Bowel Diseases, Microbiota","enrollment":13},{"nctId":"NCT01666769","phase":"PHASE1","title":"Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation","status":"COMPLETED","sponsor":"Kevin Watt","startDate":"2013-01","conditions":"Invasive Candidiasis","enrollment":18},{"nctId":"NCT02057289","phase":"PHASE1","title":"A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis","status":"TERMINATED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-01","conditions":"Immunocompromised, Bone Marrow Transplant, Cancer","enrollment":9},{"nctId":"NCT01200355","phase":"PHASE4","title":"Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-09-09","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome","enrollment":113},{"nctId":"NCT00036166","phase":"PHASE2","title":"Study of FK463 for the Treatment of Invasive Aspergillosis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"1999-01-29","conditions":"Aspergillosis","enrollment":326},{"nctId":"NCT00036179","phase":"PHASE2","title":"Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"1999-02-27","conditions":"Candidiasis","enrollment":75},{"nctId":"NCT00717860","phase":"PHASE3","title":"A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Fungal Infection","enrollment":121},{"nctId":"NCT01716988","phase":"","title":"Pharmacokinetics of Micafungin in Critically Ill Patients","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2012-10","conditions":"Critical Illness, Invasive Candidiasis","enrollment":19},{"nctId":"NCT01888458","phase":"PHASE2","title":"Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation (MycaCOORD)","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2013-09","conditions":"Invasive Fungal Infection","enrollment":21},{"nctId":"NCT01213823","phase":"","title":"Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Invasive Candidiasis, Candidemia","enrollment":536},{"nctId":"NCT00794703","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-11","conditions":"Fungemia, Fungal Infections","enrollment":288},{"nctId":"NCT02678598","phase":"","title":"A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2015-03","conditions":"Invasive Fungal Infections","enrollment":2555},{"nctId":"NCT02651038","phase":"PHASE4","title":"Pharmacokinetics of Micafungin During Continuous Venovenous Hemofiltration","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-05","conditions":"Candida Sepsis","enrollment":10},{"nctId":"NCT00815516","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-02","conditions":"Candidiasis","enrollment":30},{"nctId":"NCT00423163","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis","status":"WITHDRAWN","sponsor":"Astellas Pharma Inc","startDate":"2007-02","conditions":"Aspergillosis/Blood, Aspergillosis/Invasive","enrollment":""},{"nctId":"NCT01773876","phase":"PHASE3","title":"Empirical Antifungal Treatment in ICUS","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2012-07","conditions":"Invasive Candidiasis","enrollment":260},{"nctId":"NCT01344681","phase":"PHASE2","title":"Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-06","conditions":"Febrile Neutropenia, Hematological Diseases","enrollment":153},{"nctId":"NCT00106288","phase":"PHASE3","title":"Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-01","conditions":"Candidiasis","enrollment":637},{"nctId":"NCT00666185","phase":"PHASE3","title":"Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-08","conditions":"Candidiasis, Oral","enrollment":523},{"nctId":"NCT00105144","phase":"PHASE3","title":"Study of Micafungin in Patients With Invasive Candidiasis or Candidemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-09","conditions":"Candidiasis, Candidemia","enrollment":611},{"nctId":"NCT00606268","phase":"PHASE1","title":"A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-11","conditions":"Fungal Infections","enrollment":42},{"nctId":"NCT00047827","phase":"PHASE2","title":"Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2002-12","conditions":"Aspergillosis","enrollment":2},{"nctId":"NCT00665639","phase":"PHASE3","title":"Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-06","conditions":"Candidiasis, Oral","enrollment":454},{"nctId":"NCT00607763","phase":"PHASE1","title":"Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-10","conditions":"Invasive Candidiasis, Esophageal Candidiasis, Oropharyngeal Candidiasis","enrollment":9},{"nctId":"NCT01417169","phase":"PHASE2","title":"Micafungin Prevention Study for Invasive Fungal Disease in Pediatric & Adolescent Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2011-08","conditions":"Neutropenia, Fungal Disease","enrollment":112},{"nctId":"NCT01974375","phase":"PHASE3","title":"Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2012-08","conditions":"Liver Transplant Recipient","enrollment":172},{"nctId":"NCT00376337","phase":"PHASE2","title":"Micafungin Salvage Mono-therapy in Invasive Aspergillosis","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2006-06","conditions":"Invasive Aspergillosis","enrollment":17},{"nctId":"NCT00818584","phase":"PHASE1","title":"An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-08","conditions":"Candida","enrollment":13},{"nctId":"NCT01207128","phase":"PHASE2","title":"Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2011-02","conditions":"Aspergillosis","enrollment":""},{"nctId":"NCT00048750","phase":"PHASE3","title":"Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2003-01","conditions":"Invasive Fungal Infections","enrollment":104},{"nctId":"NCT00842504","phase":"PHASE1","title":"Alternate Day Micafungin: A PK Study in Pediatric Patients","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2007-07","conditions":"Fungal Infection","enrollment":15},{"nctId":"NCT01317394","phase":"","title":"Study and Analysis of Micafungin for Non-albican Candidemia: Efficacy, Risk Factor and Clinical Manifestation","status":"COMPLETED","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2010-12","conditions":"Non-albicans Candidemia","enrollment":60},{"nctId":"NCT01135589","phase":"PHASE4","title":"Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2010-04","conditions":"Neutropenia, Hematopoietic Stem Cell Transplantation, Invasive Fungal Disease","enrollment":145},{"nctId":"NCT00723073","phase":"","title":"Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-01","conditions":"Febrile Neutropenia","enrollment":323},{"nctId":"NCT00809887","phase":"PHASE1","title":"Micafungin Lock Therapy","status":"TERMINATED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-06","conditions":"Catheter-Related Fungal Infections","enrollment":20},{"nctId":"NCT00001790","phase":"PHASE1","title":"Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1998-10","conditions":"Fever, Mycoses, Neutropenia","enrollment":120},{"nctId":"NCT00001937","phase":"PHASE3","title":"Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-11","conditions":"Aspergillosis, Candidiasis, Fungemia","enrollment":800},{"nctId":"NCT00189709","phase":"PHASE3","title":"Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-08","conditions":"Invasive Candidiasis, Candidemia","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FK463","genericName":"FK463","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FK463 is a fungal cell wall synthesis inhibitor that disrupts β-glucan formation, leading to fungal cell death. Used for Invasive candidiasis, Invasive aspergillosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}